Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial-Reference-Cited by-同舟云学术

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

Published:2014-05 Issue:5 Volume:13 Page:472-481
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Giovannoni Gavin,Gold Ralf,Selmaj Krzysztof,Havrdova Eva,Montalban Xavier,Radue Ernst-Wilhelm,Stefoski Dusan,McNeill Manjit,Amaravadi Lakshmi,Sweetser Marianne,Elkins Jacob,O'Neill Gilmore

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference20 articles.

1. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis;Martin;Clin Immunol,2012

2. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis;Bielekova;Proc Natl Acad Sci USA,2006

3. An IL-2 paradox: blocking CD25 on T cells induces IL-2–driven activation of CD56bright NK cells;Martin;J Immunol,2010

4. Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis;Sheridan;Mult Scler,2011

5. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis;Perry;Sci Transl Med,2012

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Idiosyncratic Adverse Drug Reactions;Reference Module in Biomedical Sciences;2024

2. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

3. Cellular Cytotoxicity and Multiple Sclerosis;Cytotoxicity [Working Title];2022-06-29

4. What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?;Neurotherapeutics;2022-04

5. Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis;Human Antibodies;2021-11-22